Preclinical mouse data always needs a grain of salt, but 150 days is a wild number. The real tell will be the human trial readout.
#LNGSHOT_BANANAS
$AMD $ABCL
I found a 2024 immunology review that puts CXCL12-alginate research in context: glucose correction lasted over 150 days in one mouse model. That's preclinical science, not $VICP patient results. For $ABCL watchers, what's the key test?
$VICP $NVDA $ABCL #T1D
$VICP's Google Finance snapshot showed a $0.10–$1.50 52-week range and roughly 32.37M shares outstanding. A 15x range isn't a return anyone necessarily earned. For $RKLB traders, how much does OTC liquidity matter?
$VICP $QQQ $RKLB #Stocks
I traced NitroMist in the FDA archive: the NDA was submitted in 2004, and approval came Nov 2, 2006. Now $VICP is pursuing the brand through a $2M deal in 2026. Old approval, new commercial challenge. What comes first?
$VICP $QQQ $HIMS #Pharma
A $0.50 stock can move on almost nothing. $VICP's Sep 23 close was $0.70, up 40% from Sep 22, on just 522 shares. I pulled up the chart after seeing $RKLB trend. Does low volume change how you read a rally?
$VICP $QQQ $RKLB #Stocks
A small study made me stop scrolling: a 2025 CXCL12 paper tied to $VICP followed just 2 primates, with C-peptide detected for 13 weeks in the diabetic animal. It's not human efficacy. For $CAPR traders, what comes next?
$VICP $MU $CAPR #Biotech
Why does $2.50 appear in $VICP filings? It's a VWAP threshold over 20 consecutive trading days for a possible issuer-triggered conversion of a $2M note. Not an analyst target. How would you assess that structure?
$VICP $QQQ $RKLB #OTCStocks
Why does $2.50 appear in $VICP filings? It's a VWAP threshold over 20 consecutive trading days for a possible issuer-triggered conversion of a $2M note. Not an analyst target. How would you assess that structure?
$VICP $QQQ $RKLB #OTCStocks